Medicine Description sugarlo 50 mg
sugarlo 50 mg 30 tablets is a medication intended for the management of type 2 diabetes mellitus. Its active component, Vildagliptin, is classified as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. This medication functions by enhancing the physiological incretin levels in the body, which are hormones released by the intestines in response to food intake. By inhibiting DPP-4, Vildagliptin prolongs the action of incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). These hormones increase insulin secretion from the pancreas in a glucose-dependent manner and decrease glucagon secretion, leading to a reduction in hepatic glucose production. Consequently, this coordinated action contributes to improved glycemic control in individuals with type 2 diabetes.
Indications and Uses of sugarlo 50 mg 30 tablets
- Management of type 2 diabetes mellitus as part of a comprehensive treatment plan including diet and exercise.
- May be used alone or in conjunction with other oral antidiabetic agents.
- Adjunct treatment for patients who cannot achieve adequate glycemic control with diet and exercise alone.
Side Effects of sugarlo 50 mg 30 tablets
- Headache
- Dizziness
- Upper respiratory tract infection
- Nausea
- Diarrhea
- Hypoglycemia (especially in combination with other antidiabetic medications)
Storage and Handling
Store sugarlo 50 mg 30 tablets at room temperature, away from light and moisture. Keep out of reach of children and do not use after the expiration date printed on the package.
Patient Advice and Precautions
Monitor blood sugar levels regularly to assess the effectiveness of the therapy. Patients should be advised to maintain a balanced diet and adhere to prescribed exercise regimens. Report any signs of persistent gastrointestinal disturbances or skin reactions to a healthcare provider. Caution is advised in patients with renal impairment; dosage adjustments may be necessary.